Noninvasive assessment of liver fibrosis.
Understanding of the pathogenesis of hepatic fibrosis on a molecular level has led to the identification of several putative serum markers of hepatic fibrosis. Either individually or in combination, these serum markers appear capable of determining early and advanced hepatic fibrosis. Radiological determination of hepatic fibrosis has insufficient sensitivity and specificity other than for detection of features of portal hypertension or features of end-stage cirrhosis. Transient hepatic elastography is a novel technology demonstrating promise as a noninvasive means of fibrosis determination. This article outlines the accuracy of all these modalities in the diagnosis of hepatic fibrosis and discusses how they may be incorporated into clinical practice.
Kelleher
T Barry
TB
Department of Hepatology, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 8E, Boston, MA 02215, USA.
Afdhal
Nezam
N
D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood / Q000175:diagnosis* / Q000000981:diagnostic imaging; D011859:Radiography
D015415:Biomarkers